HomeCompareJNJ vs NKE

JNJ vs NKE: Dividend Comparison 2026

JNJ yields 2.14% · NKE yields 3.16%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NKE wins by $1.82M in total portfolio value
10 years
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →
NKE
NKE
● Live price
3.16%
Share price
$51.24
Annual div
$1.62
5Y div CAGR
66.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.85M
Annual income
$1,337,341.87
Full NKE calculator →

Portfolio growth — JNJ vs NKE

📍 NKE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNJNKE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNJ + NKE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNJ pays
NKE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
NKE
Annual income on $10K today (after 15% tax)
$268.74/yr
After 10yr DRIP, annual income (after tax)
$1,136,740.59/yr
At 15% tax rate, NKE beats the other by $1,132,703.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNJ + NKE for your $10,000?

JNJ: 50%NKE: 50%
100% NKE50/50100% JNJ
Portfolio after 10yr
$941.1K
Annual income
$671,045.87/yr
Blended yield
71.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NKE right now

JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
NKE
Analyst Ratings
1
Strong
42
Buy
23
Hold
4
Sell
Consensus: Buy
Price Target
$75.35
+47.1% upside vs current
Range: $62.00 — $110.00
Altman Z
3.8
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNJ buys
8
NKE buys
0
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNJNKE
Forward yield2.14%3.16%
Annual dividend / share$5.20$1.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28%66.3%
Portfolio after 10y$30.5K$1.85M
Annual income after 10y$4,749.88$1,337,341.87
Total dividends collected$15.6K$1.78M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$228.73$75.35

Year-by-year: JNJ vs NKE ($10,000, DRIP)

YearJNJ PortfolioJNJ Income/yrNKE PortfolioNKE Income/yrGap
1← crossover$10,594$274.49$11,226$525.77$632.00NKE
2$11,294$360.69$12,929$917.32$1.6KNKE
3$12,133$476.91$15,476$1,642.01$3.3KNKE
4$13,156$635.42$19,614$3,054.78$6.5KNKE
5$14,432$854.61$27,004$6,017.26$12.6KNKE
6$16,056$1,162.76$41,770$12,875.77$25.7KNKE
7$18,175$1,604.53$75,648$30,954.02$57.5KNKE
8$21,009$2,252.68$168,071$87,127.77$147.1KNKE
9$24,911$3,229.73$480,693$300,856.83$455.8KNKE
10$30,458$4,749.88$1,851,684$1,337,341.87$1.82MNKE

JNJ vs NKE: Complete Analysis 2026

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

NKEConsumer Discretionary

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Full NKE Calculator →
📬

Get this JNJ vs NKE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNJ vs ABBVJNJ vs MRKJNJ vs PFEJNJ vs BMYJNJ vs LLYJNJ vs SCHDJNJ vs JEPIJNJ vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.